Replimune Group (REPL)
(Delayed Data from NSDQ)
$9.86 USD
+0.13 (1.34%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $9.85 -0.01 (-0.10%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
REPL 9.86 +0.13(1.34%)
Will REPL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for REPL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for REPL
Replimune (REPL) Gains on Positive Data From Melanoma Study
How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%
REPL: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Replimune Group, Inc. (REPL) a New Buy Stock
Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High?
Incyte (INCY) Beats on Q2 Earnings and Revenue Estimates
Other News for REPL
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Replimune Group (REPL) and Hookipa Pharma (HOOK)
Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
Replimune announces first patient dosed in IGNYTE-3 trial
Replimune Group price target lowered by $3 at JPMorgan, here's why
Replimune Group (REPL) Gets a Buy from Barclays